Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Sponsor

Jonsson Comprehensive Cancer Center (Other)

Overall Status

Completed

CT.gov ID

NCT00003225

Collaborator

ALZA (Industry)

Enrollment

Locations

Arm

Duration (Months)

11.5

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with metastatic colorectal cancer.

Condition or Disease	Intervention/Treatment	Phase
Colorectal Cancer	Drug: amifostine trihydrate Drug: irinotecan hydrochloride	Phase 1/Phase 2

Detailed Description

OBJECTIVES: I. Assess the toxicity profile of irinotecan and amifostine when administered together in patients with metastatic colorectal cancer. II. Assess the total dose of irinotecan received per 6 week course in these patients. III. Determine the incidence of irinotecan-induced leukopenia, neutropenia, and diarrhea in these patients. V. Determine the response rate for this patient population.

OUTLINE: This is an open label study. Amifostine is administered by 10 minute IV infusions. Irinotecan is administered by IV infusions 15 minutes after completion of amifostine. Treatment is repeated every 2 weeks for 6 weeks. This 6 week course is repeated in the absence of disease progression. Treatment may be delayed up to 2 weeks after a course to allow for recovery from toxic effects. Patients are followed at the end of study and at 30 days after study.

PROJECTED ACCRUAL: There will be 25-30 patients accrued into this study.

Study Design

Study Type:

Interventional

Actual Enrollment :

23 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer

Study Start Date :

Jul 1, 1997

Actual Primary Completion Date :

Mar 1, 2000

Actual Study Completion Date :

Jun 1, 2001

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ethyol plus Irinotecan Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.	Drug: amifostine trihydrate Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles. Other Names: Ethyol Drug: irinotecan hydrochloride 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV. Administered every 14 days for 3 cycles

Arm

Intervention/Treatment

Experimental: Ethyol plus Irinotecan

Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.

Drug: amifostine trihydrate

Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.

Other Names:

Ethyol

Drug: irinotecan hydrochloride

10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV. Administered every 14 days for 3 cycles

Outcome Measures

Primary Outcome Measures

To assess the toxicity profile of Irinotecan and Ethyol when administered together on this schedule. [12 weeks]

Secondary Outcome Measures

To assess the total dose of Irinotecan received per 6 week cycle [6 weeks]
To determine incidence of Irinotecan-induced leukopenia and neutropenia [12 weeks]
To determine the incidence of Irinotecan-induced diarrhea [12 weeks]
To determine the response rate for patients with metastatic colorectal carcinoma receiving Irinotecan and Ethyol on this dosing schedule (as measured by time response, duration of response time to progression, time of treatment failure survival). [12 weeks]
To determine the clinical benefit of intravenous Irinotecan and Ethyol in patients with colorectal cancer, as measured by performance status, analgesic consumption, quality of life and survival. [12 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

18 years of age or older
ECOG 0-2
Life expectancy of at least 12 weeks
Pathologically confirmed diagnosis of metastatic colorectal cancer
Measureable disease
Have not received therapy for cancer within 4 weeks of enrollment on study
Prior radiation therapy to the pelvis for treatment of colorectal cancer is allowed. Radiation therapy delivered elsewhere is allowed as long as the patient has been off treatment for at least six weeks and measurable lesions are present outside the radiation field
Pretreatment granulocyte count of > 1500/mm3, hemoglobin > 9.0 g/dL (without transfusion), and platelet count of > 100,000/um
Serum creatinine < 2.0 mg/dL
Adequate hepatic function as documented by a serum bilirubin < 2.0 mg/dL regardless of whether patients have liver involvement secondary to tumor. AST must be < 3x the upper limit of normal unless the liver is involved with tumor, in which case the AST must be < 5x institutional upper limit of normal

Exclusion Criteria:

Prior therapy with Irinotecan
Patients with any active or uncontrolled infection
Patients with psychiatric disorders that would interfere with consent or follow-up
Patients with a history of myocardial infarction within the previous six months, congestive heart failure, or cerebrovascular disease
History of prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years
Presence of clinically apparent central nervous system metastases or carcinomatous meningitis
Patients with uncontrolled diabetes mellitus
Any other sever concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Patients unable to stop taking antihypertensive medication 24 hour prior to administration of Ethyol (off x 1 day)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Jonsson Comprehensive Cancer Center, UCLA	Los Angeles	California	United States	90095-1781
2	Wilshire Oncology Medical Group, Inc.	Rancho Cucamonga	California	United States	91730